Centralized Status Rejected for Tylenol Liver-Injury Suits

The New Jersey Supreme Court has rejected yet another application — again by a defendant — for centralization under Rule 4:38A.  As we previously noted, Johnson & Johnson earlier this year submitted an application seeking centralization of all suits alleging liver damage from the ingestion of Tylenol in Middlesex County.  J&J’s application came on the heels of the establishment of a federal MDL on the same issue. In a notice dated last month and released last week, the NJ Supreme Court rejected J&J’s request. …
Continue reading...

Centralized Management Denied for Bayer’s Mirena Claims

In a decision reached earlier this month and posted last week, the New Jersey Supreme Court has denied an application submitted by Bayer HealthCare Pharmaceuticals, Inc. for centralized management of all pending state court actions involving its Mirena contraceptive device.  No reasons for the denial are provided in the notice, so practitioners in this area are left without any guidance as to why the Supreme Court rejected the application.  This is similar to the Supreme Court’s previous denial of centralization of the litigation involving NexGen…
Continue reading...